ANRS, Emerging Infectious Diseases
anrs.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
213
Active
39
Phase 3
41
Total enrollment
15,257,718
Pipeline matrix
Showing 40 of 49 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ACCESS+ strategy Epclusa 400/100 Oral | — | — | — | — | — | 1 | |
| ACCESS+ Strategy Vosevi 400/100/100 Oral | — | — | — | — | — | 1 | |
| Standard Strategy Vosevi 400/100/100 Oral | — | — | — | — | — | 1 | |
| Standard Strategy Epclusa 400/100 Oral | — | — | — | — | — | 1 | |
| Fumarate, Tenofovir Disoproxil | — | — | — | — | — | 1 | |
| Ervebo | — | — | — | — | 3 | ||
| Inmazeb | — | — | — | — | 2 | ||
| Doravirine + tenofovir DF + lamivudine | — | — | — | — | — | 1 | |
| Dolutegravir + tenofovir DF + lamivudine or emtricitabine | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | — | 1 | |
| WHO TBM treatment | — | — | — | — | — | 1 | |
| Intensified TBM treatment | — | — | — | — | — | 1 | |
| Tecovirimat | — | — | — | — | — | 1 | |
| TDF/FTC 300mg/200mg fixed-dose combination | — | — | — | — | — | 1 | |
| TAF/FTC 25mg/200mg fixed-dose combination | — | — | — | — | — | 1 | |
| Cabotegravir Tablets, for oral use. | — | — | — | — | — | 1 | |
| Cabotegravir Extended-Release Injectable Suspension, for intramuscular use. | — | — | — | — | — | 1 | |
| Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Baricitinib 2 MG | — | — | — | — | — | 1 | |
| Sirolimus 2 MG | — | — | — | — | — | 1 | |
| LVT-001 | — | — | — | — | — | 1 | |
| Cormirnaty | — | — | — | — | — | 1 | |
| Recombinant human monoclonal antibody | — | — | — | — | — | 1 | |
| TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI | — | — | — | — | — | 1 | |
| Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir | — | — | — | — | — | 1 | |
| CD40.RBDv vaccin | — | — | — | — | — | 1 | |
| Paxlovid 5 days | — | — | — | — | — | 1 | |
| Paxlovid 10 days | — | — | — | — | — | 1 | |
| Veklury | — | — | — | — | — | 1 | |
| CD40.Pan.CoV Low dose | — | — | — | — | — | 1 | |
| CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol® | — | — | — | — | — | 1 | |
| CD40.Pan.CoV High dose | — | — | — | — | — | 1 | |
| CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol® | — | — | — | — | — | 1 | |
| CD40.RBDv vaccine adjuvanted with Hiltonol® | — | — | — | — | — | 1 | |
| CD40.Pan.CoV vaccine adjuvanted with Hiltonol® | — | — | — | — | — | 1 | |
| Comirnaty® vaccine | — | — | — | — | — | 1 | |
| Nuvaxovid™ vaccine | — | — | — | — | — | 1 | |
| Blood sampling | — | — | — | — | — | 4 | |
| Treatment by TDF if HBcrAg RDT positive | — | — | — | — | — | 1 |
9 more active programs hidden
Next readouts
- 2024-11-01
- 2025-09
- 2025-10-30
- 2026-01-31
- 2026-06-30
- 2026-09-23
- 2026-09-30
- 2026-10
- 2026-10
- 2026-10-08
Top conditions
- HIV Infections37
- HIV Infection26
- HIV-1 Infection18
- HIV14
- HIV-1-infection10
- Tuberculosis10
- Hepatitis C9
- COVID-198
Frequently asked questions about ANRS, Emerging Infectious Diseases
- How many clinical trials does ANRS, Emerging Infectious Diseases have on ClinicalTrials.gov?
- ANRS, Emerging Infectious Diseases is listed as the lead sponsor on 213 clinical trials in ClinicalTrials.gov, 39 of which are currently active (recruiting, enrolling, or ongoing).
- How many of ANRS, Emerging Infectious Diseases's trials are in Phase 3?
- 41 of ANRS, Emerging Infectious Diseases's trials are in Phase 3, spread across 49 active drug programs.
- What therapeutic areas does ANRS, Emerging Infectious Diseases focus on?
- ANRS, Emerging Infectious Diseases's most-studied conditions on ClinicalTrials.gov are HIV Infections, HIV Infection, HIV-1 Infection, HIV, HIV-1-infection.
- When are ANRS, Emerging Infectious Diseases's next clinical trial readouts?
- ANRS, Emerging Infectious Diseases has 10 upcoming primary-completion readouts tracked here; the soonest is “Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination”, expected around 2024-11-01.